Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garrett-Mayer

Showing results (221-230 of 275) with videos related to

Pageof 28
Sort By:
JCO Precision Oncology|June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry StudyApar K Ganti, Michael Rothe, Pam K Mangat, et al.
Journal of Leukocyte Biology|February 28, 2016
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instabilityTimothy T Spear, Timothy P Riley, Gretchen E Lyons, et al.
JCO Precision Oncology|April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR StudyEugene R Ahn, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyVaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
Cancer Research|July 29, 2016
Lack of p53 Augments Antitumor Functions in Cytolytic T CellsAnirban Banerjee, Krishnamurthy Thyagarajan, Shilpak Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker StudyKala Visvanathan, MaryJo S Fackler, Zhe Zhang, et al.
EMBO Molecular Medicine|November 28, 2012
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosisSahar A Saddoughi, Salih Gencer, Yuri K Peterson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 17, 2012
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in miceShikhar Mehrotra, Amir A Al-Khami, Jared Klarquist, et al.
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Pageof 28

Showing results (221-230 of 275) with videos related to

Sort By:
Pageof 28
JCO Precision Oncology|June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry StudyApar K Ganti, Michael Rothe, Pam K Mangat, et al.
Journal of Leukocyte Biology|February 28, 2016
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instabilityTimothy T Spear, Timothy P Riley, Gretchen E Lyons, et al.
JCO Precision Oncology|April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR StudyEugene R Ahn, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyVaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
Cancer Research|July 29, 2016
Lack of p53 Augments Antitumor Functions in Cytolytic T CellsAnirban Banerjee, Krishnamurthy Thyagarajan, Shilpak Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker StudyKala Visvanathan, MaryJo S Fackler, Zhe Zhang, et al.
EMBO Molecular Medicine|November 28, 2012
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosisSahar A Saddoughi, Salih Gencer, Yuri K Peterson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 17, 2012
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in miceShikhar Mehrotra, Amir A Al-Khami, Jared Klarquist, et al.
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Pageof 28